1)  Rosiglitazone
文迪雅
1.
Clinical Study of Short-term Continuously Subcutaneous Insulin Infusion Combined with Rosiglitazone in Intensively Treating Newly Diagnosed Type 2 Diabetes Mellitus;
短期胰岛素泵联合文迪雅强化治疗初诊2型糖尿病临床研究
2.
Objective Rosiglitazone and Metformine are used together to cure type Ⅱ diabetes mellitus and make an observation of their treatment outcome.
目的 :联合应用文迪雅和二甲双胍治疗Ⅱ型糖尿病疗效观察。
3.
Experimental groups were randomly divided into Dioscorea nipponica Makino group, rosiglitazone group and control group.
实验组随机分为穿山龙组、文迪雅组、对照组,以高脂饲料饲养一个月+腹腔注射小剂量链脲佐菌素(30mg/Kg)制备胰岛素抵抗的糖尿病大鼠模型,以非空腹血糖(GLU)≥16。
2)  Rosiglitazone
罗格列酮钠
1.
An influence of rosiglitazone on glycaemic and lipid metabolism and insulin resistance of T2DM patients;
罗格列酮钠对2型糖尿病患者糖脂代谢及胰岛素抵抗的影响
2.
Objective To study the effects of Rosiglitazone,a synthetic ligand of peroxisome proliferator activated receptorγ on the expression of proinflammatory factors in myocardial hypertrophic rats.
目的探讨过氧化酶体增殖物激活型受体(PPARγ)配体-罗格列酮钠对压力负荷所致肥厚心肌中炎性因子的影响。
3)  Rosiglitazone
马来酸罗格列酮
1.
Effect of Metformin and Rosiglitazone Treatment on Polycystic Ovary Syndrome;
盐酸二甲双胍和马来酸罗格列酮治疗多囊卵巢综合征的临床研究
2.
Objectives: To investigate the effects of advanced glycation end products(AGEs)on the expression of fractalkine(FKN, CX3CL1)in cultured human renal mesangial cells (HRMC), and the influence of Rosiglitazone, Irbesartan and Aminoguanidine on the FKN expression.
目的:观察糖基化终产物(advanced glycation end products,AGEs)对人肾系膜细胞(human renal mesangial cell,HRMC)的fractalkine(FKN,CX3CL1)表达的影响以及马来酸罗格列酮等药物干预作用;观察2型糖尿病大鼠血清糖基化终产物肽(AGE-peptide,AGE-P)水平和肾皮质FKN表达以及马来酸罗格列酮等药物干预作用。
4)  Rosiglitazone
Rosiglitazone
5)  Rosiglitazone
罗格列酮（文迪雅）
6)  Rosiglitazone
固醇调节元件结合蛋白1c
1.
Study on Fatty Liver Disease of Macroangiopathy in Rat Model of Type 2 Diabetes Mellitus and the Effect of Rosiglitazone Interence;
NAFLD的确切发病机制尚未完全阐明,其中以固醇调节元件结合蛋白1c(SREBP-1c)及过氧化物酶体增值物激活受体γ辅激活因子1α(PGC-1α)为调控中心的糖、脂代谢紊乱,胰岛素抵抗等在NAFLD的发生发展过程中可能起着重要作用。
参考词条
补充资料：雅文
1.犹文雅。 2.雅正的文辞，。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。